The study commencement is based on previous clinical safety and efficacy data, along with robust preclinical evidence.

While infections pose a risk for morbidity and mortality among patients with MDS, more needs to be studied about the topic, ...

Among patients with myelodysplastic syndromes (MDS), treatment with Reblozyl (luspatercept) resulted in at least 12 weeks of ...

for the treatment of myelodysplastic syndromes (MDS). “Receiving orphan drug designation for tebapivat in MDS underscores the importance of bringing new oral treatment options to patients ...

(RTTNews) - Agios Pharmaceuticals, Inc. (AGIO) Wednesday said the Food and Drug Administration or FDA has granted orphan drug designation to the company's drug candidate tebapivat for the treatment of ...

Agios on Wednesday said the designation covers tebapivat for the treatment of myelodysplastic syndromes, or MDS, in which immature blood cells in the bone marrow don't mature or become healthy blood ...

Tebapivat, a novel pyruvate kinase activator, is being investigated for the treatment of anemia in patients with lower-risk ...

DNA hypomethylating agents (HMAs) are used for the treatment of myeloid malignancies, but their therapeutic effects are not satisfactory. Here, the authors show that inhibition of TOPORS, which ...

Patients with myelodysplastic syndromes report high satisfaction with oral decitabine/cedazuridine (DEC-C) vs traditional intravenous or subcutaneous hypomethylating agents. Traditionally ...

Ongoing research is exploring new molecular targets and targeted therapies for this challenging disease.

Bexmarilimab is under clinical development by Faron Pharmaceuticals and currently in Phase II for Myelodysplastic Syndrome.